Literature DB >> 7419648

Two high-performance liquid chromatographic determinations for mebendazole and its metabolites in human plasma using a rapid Sep Pak C18 extraction.

R J Allan, H T Goodman, T R Watson.   

Abstract

A rapid extraction procedure for mebendazole and its metabolites from plasma using Sep Pak C18 is described. This method eliminates the need for solvent extractions as such. Two reversed-phase high-performance liquid chromatographic determinations for these extracts, one isocratic elution and the other gradient elution, using an analytical wavelength of 254 nm are also presented. The gradient elution system provides superior resolution of these compounds and consequently has improved determination limits. For mebendazole the determination limits are 20 ng/ml (isocratic system) and 10 ng/ml (gradient system).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7419648     DOI: 10.1016/s0378-4347(00)81711-9

Source DB:  PubMed          Journal:  J Chromatogr


  9 in total

Review 1.  Clinical pharmacokinetics of anthelmintic drugs.

Authors:  G Edwards; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

2.  The metabolic and pharmacokinetic disposition of mebendazole in the rat.

Authors:  R J Allan; T R Watson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

Review 3.  Chemotherapy for larval echinococcosis in animals and humans: report of a workshop.

Authors:  P M Schantz; H Van den Bossche; J Eckert
Journal:  Z Parasitenkd       Date:  1982

4.  The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.

Authors:  M Dawson; P A Braithwaite; M S Roberts; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

5.  4-Amino-3-(3'-methoxycarbonyl-2'-thioureido)benzophenone, a prodrug of mebendazole.

Authors:  M Dawson; T R Watson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

6.  Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis.

Authors:  F Witassek; R J Allan; T R Watson; W Woodtli; R Ammann; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Chemotherapy of larval echinococcosis with mebendazole: microsomal liver function and cholestasis as determinants of plasma drug level.

Authors:  F Witassek; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Identification of biliary metabolites of mebendazole in the rat.

Authors:  R J Allan; T R Watson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

9.  Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease.

Authors:  P A Braithwaite; M S Roberts; R J Allan; T R Watson
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.